Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia
Background and Purpose: Multiple system atrophy with predominant cerebellar ataxia is a disabling neurologic disease. However, effective management has not yet been established. We conducted a short-term, open-label preliminary study to assess the benefits of intravenous amantadine treatment in pati...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Movement Disorder Society
2012-05-01
|
| Series: | Journal of Movement Disorders |
| Subjects: | |
| Online Access: | http://e-jmd.org/upload/jmd-5-1-1-1.pdf |
| _version_ | 1827881438263902208 |
|---|---|
| author | Jinyoung Youn Hyeeun Shin Ji Sun Kim Jin Whan Cho |
| author_facet | Jinyoung Youn Hyeeun Shin Ji Sun Kim Jin Whan Cho |
| author_sort | Jinyoung Youn |
| collection | DOAJ |
| description | Background and Purpose: Multiple system atrophy with predominant cerebellar ataxia is a disabling neurologic disease. However, effective management has not yet been established. We conducted a short-term, open-label preliminary study to assess the benefits of intravenous amantadine treatment in patients with probable multiple system atrophy with predominant cerebellar ataxia. Methods: Twenty patients (10 male, 10 female) with probable multiple system atrophy with predominant cerebellar ataxia received 400 mg of amantadine by intravenous per day for 5 days. Ataxia severity was evaluated by the International Cooperative Ataxia Rating Scale before and after intravenous amantadine therapy and all subjects reported subjective improvement after intravenous amantadine treatment using a patient global impression scale. We analyzed the total and subscale scores by the ataxia scale and patient global impression scale. Results: The mean age was 57.4 years (range: 47–72) and the mean disease duration was 30.8 months (range: 11–79). The ataxia severity significantly decreased after intravenous amantadine therapy from 42.5 to 37.3 (p < 0.001). The mean patient global impression scale for improvement was 2.9 and there were no side effects of intravenous amantadine treatment observed. When we assessed responders, the duration of intravenous amantadine effect was more than 1 month in 4 subjects of 7 responders. Conclusions: Our findings suggest that intravenous amantadine treatment can be a safe management option in cerebellar ataxia, although the mechanism is unclear. Thus, further double-blind, long-term studies with a larger sample size are needed. |
| first_indexed | 2024-03-12T18:38:31Z |
| format | Article |
| id | doaj.art-16702d2b849c4e92b9adeec6a4f6df20 |
| institution | Directory Open Access Journal |
| issn | 2005-940X 2093-4939 |
| language | English |
| last_indexed | 2024-03-12T18:38:31Z |
| publishDate | 2012-05-01 |
| publisher | Korean Movement Disorder Society |
| record_format | Article |
| series | Journal of Movement Disorders |
| spelling | doaj.art-16702d2b849c4e92b9adeec6a4f6df202023-08-02T07:54:42ZengKorean Movement Disorder SocietyJournal of Movement Disorders2005-940X2093-49392012-05-01511410.14802/jmd.1200110Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar AtaxiaJinyoung YounHyeeun ShinJi Sun KimJin Whan ChoBackground and Purpose: Multiple system atrophy with predominant cerebellar ataxia is a disabling neurologic disease. However, effective management has not yet been established. We conducted a short-term, open-label preliminary study to assess the benefits of intravenous amantadine treatment in patients with probable multiple system atrophy with predominant cerebellar ataxia. Methods: Twenty patients (10 male, 10 female) with probable multiple system atrophy with predominant cerebellar ataxia received 400 mg of amantadine by intravenous per day for 5 days. Ataxia severity was evaluated by the International Cooperative Ataxia Rating Scale before and after intravenous amantadine therapy and all subjects reported subjective improvement after intravenous amantadine treatment using a patient global impression scale. We analyzed the total and subscale scores by the ataxia scale and patient global impression scale. Results: The mean age was 57.4 years (range: 47–72) and the mean disease duration was 30.8 months (range: 11–79). The ataxia severity significantly decreased after intravenous amantadine therapy from 42.5 to 37.3 (p < 0.001). The mean patient global impression scale for improvement was 2.9 and there were no side effects of intravenous amantadine treatment observed. When we assessed responders, the duration of intravenous amantadine effect was more than 1 month in 4 subjects of 7 responders. Conclusions: Our findings suggest that intravenous amantadine treatment can be a safe management option in cerebellar ataxia, although the mechanism is unclear. Thus, further double-blind, long-term studies with a larger sample size are needed.http://e-jmd.org/upload/jmd-5-1-1-1.pdfAtaxiaAmantadineCerebellarMultiple system atrophyIntravenousNMDA |
| spellingShingle | Jinyoung Youn Hyeeun Shin Ji Sun Kim Jin Whan Cho Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia Journal of Movement Disorders Ataxia Amantadine Cerebellar Multiple system atrophy Intravenous NMDA |
| title | Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia |
| title_full | Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia |
| title_fullStr | Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia |
| title_full_unstemmed | Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia |
| title_short | Preliminary Study of Intravenous Amantadine Treatment for Ataxia Management in Patients with Probable Multiple System Atrophy with Predominant Cerebellar Ataxia |
| title_sort | preliminary study of intravenous amantadine treatment for ataxia management in patients with probable multiple system atrophy with predominant cerebellar ataxia |
| topic | Ataxia Amantadine Cerebellar Multiple system atrophy Intravenous NMDA |
| url | http://e-jmd.org/upload/jmd-5-1-1-1.pdf |
| work_keys_str_mv | AT jinyoungyoun preliminarystudyofintravenousamantadinetreatmentforataxiamanagementinpatientswithprobablemultiplesystematrophywithpredominantcerebellarataxia AT hyeeunshin preliminarystudyofintravenousamantadinetreatmentforataxiamanagementinpatientswithprobablemultiplesystematrophywithpredominantcerebellarataxia AT jisunkim preliminarystudyofintravenousamantadinetreatmentforataxiamanagementinpatientswithprobablemultiplesystematrophywithpredominantcerebellarataxia AT jinwhancho preliminarystudyofintravenousamantadinetreatmentforataxiamanagementinpatientswithprobablemultiplesystematrophywithpredominantcerebellarataxia |